Narrow Results

Common Epilepsy Gene Discovered.

Peptide Found May Eliminate Anthrax.

Strong Demand for AEDs in Japan.

Fast Antibodies Peptide Mapping Solution from Agilent.

Thomson to Acquire Information Holdings.

Agilent Technologies licenses SureFISH to BioDiscovery.

Bionomics acquires US-based cancer stem cell company Eclipse Therapeutics.

AB SCIEX announces Biologics Initiative.

Phylogica licences skin-repair peptide to Le Métier De Beauté for cosmetic market.

Brooks' Single-use REMP tubes support optimization of automated serum and plasma storage

Genetic Technologies announces key managerial appointment Mark Ostrowski to head-up US sales for BREVAGen™.

BioScience Managers banks on growth of anti-infectives market.

Rodin Therapeutics applies insights of epigenetics to neurological disorders.

LBT Innovations finalizes joint venture to drive global production of world-class automated diagnostics technology.

Phylogica expands collaborations with Janssen for peptide-drug conjugates.

Immune Design and Medicago announce license agreement and collaboration to develop novel adjuvanted pandemic influenza vaccines.

Bayat Foundation inaugurates new pediatric critical care facility at Indira Gandhi Hospital in Kabul.

The International Peptide Symposium Held in Singapore for the First Time.

Inspirations from 2015 FWIS L'Oréal Winners.

Emerging Opportunities in Myanmar's Diagnostic Imaging and In Vitro Diagnostics.

High-Throughput Sequencing on a Next Generation Sequencer to Identify Specific Binders from a Phage Library

Antibody Solution Viscosity and Intermolecular Interactions: Considerations for Development of Highly Concentrated Formulations

Display of Membrane Proteins on a Viral Envelope for Antibody Generation

Sequence and Structural Determinants of Antigen Binding in Antibody CDR Loops

Enhancement of the Stability of Single Chain Fv Molecules with the Amino Acid Substitutions Predicted by High-Performance Computer

Thermal Stability of Camelid Single Domain VHH Antibody

Porphyrin-peptide conjugates have a breadth of potential applications, including use in photodynamic therapy, boron neutron capture therapy, as fluorescence imaging tags for tracking subcellular localization, as magnetic resonance imaging (MRI) positive-contrast reagents and as biomimetic catalysts. Here, we have explored three general routes to porphyrin-peptide conjugates using the Cu(I)-catalyzed Huisgen-Medal-Sharpless 1,3-dipolar cycloaddition of peptide-containing azides with a terminal alkyne-containing porphyrin, thereby generating porphyrin-peptide conjugates (PPCs) comprised of a cationic porphyrin coupled to short antimicrobial peptides. In addition to characterizing the PPCs using a variety of spectroscopic (UV-vis, ¹H- and ¹³C-NMR) and mass spectrometric methods, we evaluated their efficacy as photosensitizers for the in vitro photodynamic inactivation of Mycobacterium smegmatis as a model for the pathogen Mycobacterium tuberculosis. Difficulties that needed to be overcome for the efficient synthesis of PPCs were the limited solubility of the quaternized pyridyl porphyrin in common solvents, undesired (de)metallation and transmetallation, and chromatographic purification. Photodynamic inactivation studies of a small library of PPCs against Mycobacterium smegmatis confirmed our hypothesis that the porphyrin-based photosensitizer maintains its ability to efficiently inactivate bacteria when conjugated to a small peptide by upwards of 5–6 log units (99.999+%) using white light illumination (400–700 nm, 60 mW/cm², 30 min). Further, hemolysis assays revealed the lack of toxicity of the PPCs against sheep blood at concentrations employed for in vitro photodynamic inactivation. Taken together, the results demonstrated the ability of PPCs to maintain their antimicrobial photodynamic inactivation efficacy when possessing a short cationic peptides for enabling the potential targeting of pathogens in vivo.